Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

This is an early-stage study testing a new cell therapy called B019 injection in patients whose B-cell non-Hodgkin's lymphoma has returned or not responded to previous treatments. The main goals are to find a safe dose and see how well patients tolerate the treatment, while also …